Journal article
PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years
Radiotherapy and oncology, Vol.141, pp.188-191
01/12/2019
PMID: 31668514
Metrics
15 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Abstract
Purpose/objectives
There are no published reports of prostate specific membrane antigen (PSMA) positron emission tomography (PET) guided dose-escalated intensity-modulated radiation therapy (DE-IMRT) in newly diagnosed lymph node (LN) positive prostate cancer. We report early toxicity and efficacy outcomes with this approach.
Materials/methods
Patients with newly diagnosed high-risk prostate cancer were staged using PSMA PET, computed tomography (CT) and bone scans. Patients with LN positive-only metastases were offered curative therapy using 3 months androgen deprivation therapy (ADT) followed by DE-IMRT (using volumetric arc therapy), and 3 years adjuvant ADT. All patients had fiducial marker insertion, with privately insured patients having spacer hydrogel insertion. PET and prostate magnetic resonance imaging were fused with the planning CT. We aimed to deliver 81 Gy in 45 fractions (Fx) to the prostate and PET-positive LNs, and 60 Gy in 45Fx to bilateral elective pelvic LNs.
Results
In all, 46 patients were treated, with 83% Gleason 8–10, 67% T3/T4, median number of LNs 2 (range 1–6), and median PET-positive LN volume 1.14 cc (range 0.15–4.14). LNs were outside of standard contouring guidelines in 37% of patients. The mean PET-positive LN clinical target volume dose ranged from 73.3 to 85.9 Gy (median 83.6 Gy). With 24 months median follow-up, two year failure-free survival was 100%, and 2 year overall survival 95.7%. Acute grade 1 and 2 GI toxicity occurred in 48 and 11% of patients, and GU toxicity in 72 and 24%. Late grade 1, 2 and 3 GI toxicity occurred in 13, 2 and 0%, and GU toxicity 28, 13 and 4%. No toxicity was attributable to the high dose LN boost.
Conclusions
PSMA PET-guided DE-IMRT up to 81 Gy to the prostate and involved LNs, and long term ADT, is a promising approach for newly diagnosed LN positive prostate cancer. LN contouring guidelines require re-evaluation in the era of PSMA PET imaging.
Details
- Title
- PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years
- Creators
- Thomas Philip Shakespeare - Mid North Coast Cancer Institute, Coffs HarbourElizabeth Eggert - Mid North Coast Cancer Institute, Port MacquarieMaree Wood - Mid-North Coast Cancer Institute (Port Macquarie, Australia)Justin Westhuyzen - Mid-North Coast Cancer Institute (Coffs Harbour, Australia)Kirsty Turnbull - Mid-North Coast Cancer Institute (Coffs Harbour, Australia)Natalie Rutherford - John Hunter HospitalNoel Aherne - UNSW Sydney
- Publication Details
- Radiotherapy and oncology, Vol.141, pp.188-191
- Publisher
- Elsevier B.V
- Identifiers
- 991013098100602368
- Copyright
- Crown Copyright © 2019 Published by Elsevier B.V. All rights reserved.
- Academic Unit
- Coffs Harbour Campus Administration
- Language
- English
- Resource Type
- Journal article